

**IARC WORKING GROUP ON THE EVALUATION
OF CARCINOGENIC RISKS TO HUMANS:
SOME ANTIVIRAL AND ANTINEOPLASTIC DRUGS,
AND OTHER PHARMACEUTICAL AGENTS**

Lyon, 12–19 October 1999

LIST OF PARTICIPANTS

Members

- D.E. Barker, The CORE Center for Infectious Diseases, Cook County Hospital, Division of Infectious Diseases, 2020 W. Harrison Street, Chicago, IL 60612, United States
- T.A. Dragani, Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy
- J.K. Dunnick, National Institute of Environmental Health Sciences, PO Box 12233, Research Triangle Park, NC 27709, United States
- C.A. Felix, Division of Oncology, The Children's Hospital of Philadelphia, Abramson Pediatric Research Center, Room 902B, 3516 Civic Center Boulevard, Philadelphia, PA 19104-4318, United States
- L.R. Ferguson, Auckland Cancer Society Research Centre, Faculty of Medical and Health Science, The University of Auckland, Private Bag 92019, Auckland 1000, New Zealand
- S.P. Joel, Medical Oncology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, United Kingdom
- R. von Kries, Institute for Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians University, Heiglhofstrasse 63, 81377 Munich, Germany
- F.E. van Leeuwen, Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
- J. Little, Institute of Medical Sciences, Department of Medicine & Therapeutics, University of Aberdeen Medical School, Polwarth Building, Foresterhill, Aberdeen AB9 2ZD, United Kingdom
- S. Olin, International Life Sciences Institute, Risk Science Institute, 1126 Sixteenth Street NW, Washington, DC 20036, United States
- J.H. Olsen, Danish Cancer Society, Institute of Cancer Epidemiology, Box 839, 2100 Copenhagen Ø, Denmark

- M.C. Poirier, Carcinogen–DNA Interactions Section, National Cancer Institute, Building 37, Room 2A05, 37 Convent Drive, Bethesda, MD 20892-4255, United States
(*Chairperson*)
- M.J. Shearer, The Vitamin K Research Unit of the Haemophilia Centre, The Rayne Institute, 4th Floor Lambeth Wing, St Thomas’s Hospital, London SE1 7EH, United Kingdom
- W. Slikker, Jr, Division of Neurotoxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079-9502, United States
- F.M. Sullivan, Harrington House, 8 Harrington Road, Brighton, East Sussex BN1 6RE, United Kingdom
- V. Turusov, Blokhin Cancer Research Centre, Russian Academy of Medical Sciences, Kashirskoye Shosse 24, 115478 Moscow, Russian Federation
- V.E. Walker, Wadsworth Center for Laboratories and Research, New York State Department of Health, Empire State Plaza, PO Box 509, Albany, NY 12201-0509, United States

Representative/Observer

Representative of the National Cancer Institute

- S.M. Sieber, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza North, 6100 Executive Boulevard, Rockville, MD 20852, United States

Secretariat

- E. Heseltine (*Editor*), Lajarthé, 24290 St Léon-sur-Vézère, France

IARC

- R. Baan, Unit of Carcinogen Identification and Evaluation
- P. Brennan, Unit of Environmental Cancer Epidemiology
- M. Friesen, Unit of Gene–Environment Interactions
- Y. Grosse, Unit of Carcinogen Identification and Evaluation
- V. Krutovskikh, Unit of Multistage Carcinogenesis
- C. Malaveille, Unit of Endogenous Cancer Risk Factors
- D. McGregor, Unit of Carcinogen Identification and Evaluation
- C. Partensky, Unit of Carcinogen Identification and Evaluation
- J. Rice, Unit of Carcinogen Identification and Evaluation (*Head of Programme*)
- J. Wilbourn, Unit of Carcinogen Identification and Evaluation (*Responsible Officer*)

Technical assistance

- M. Lézère
- A. Meneghel
- D. Mietton
- J. Mitchell

E. Perez
S. Reynaud
J. Thévenoux